IPO

A small float helped amplify the stock’s swing, turning its IPO into a test of investor sentiment.

The drug developer has no approved products or revenue yet, but the IPO could extend its cash runway by nearly six years.

Bringing you the latest updates on funding and investment activity across the Asia Pacific.

The listing will test investor appetite for decision intelligence as the AI narrative reaches a high point.

Bringing you the latest updates on funding and investment activity across the Asia Pacific.

Bringing you the latest updates on funding and investment activity across the Asia Pacific.

The company is moving beyond traditional robots into higher-value systems designed for smart manufacturing.

Cockpit-driving integrated products sit at the center of the company’s pitch.